KR20110047280A - Oral Compositions for the Treatment of Cellulite - Google Patents
Oral Compositions for the Treatment of Cellulite Download PDFInfo
- Publication number
- KR20110047280A KR20110047280A KR1020117009257A KR20117009257A KR20110047280A KR 20110047280 A KR20110047280 A KR 20110047280A KR 1020117009257 A KR1020117009257 A KR 1020117009257A KR 20117009257 A KR20117009257 A KR 20117009257A KR 20110047280 A KR20110047280 A KR 20110047280A
- Authority
- KR
- South Korea
- Prior art keywords
- cellulite
- phospholipids
- complex
- asiatica
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 208000035484 Cellulite Diseases 0.000 title claims abstract description 13
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 13
- 230000036232 cellulite Effects 0.000 title claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 16
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 16
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 11
- 239000000539 dimer Substances 0.000 claims abstract description 11
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 10
- 229930003935 flavonoid Natural products 0.000 claims abstract description 10
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 10
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 10
- 244000146462 Centella asiatica Species 0.000 claims abstract description 9
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 9
- 240000006365 Vitis vinifera Species 0.000 claims abstract description 9
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 8
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 7
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000002282 venous insufficiency Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 abstract description 7
- 235000009754 Vitis X bourquina Nutrition 0.000 abstract description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 abstract description 3
- 241001099919 Coenogonium Species 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 241000219095 Vitis Species 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 2
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010036155 Poor peripheral circulation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000219094 Vitaceae Species 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 235000021021 grapes Nutrition 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000015438 Cola nitida Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000750042 Vini Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 230000003501 anti-edematous effect Effects 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
본 발명은 포도(Vitis vinifera) 추출물, 은행(Ginkgo biloba) 후라보노이드류 이량체 및 센텔라 아시아티카(Centella asiatica) 트리텔펜류의 유리형태 또는 인지질과의 착체를 포함하는 셀룰라이트(cellulite) 치료작용을 갖는 경구용 약제 및 화장품 조성물에 관한 것이다.The present invention is grape ( Vitis vinifera extract, Ginkgo biloba ) Flavonoid dimer and Centella asiatica asiatica ) relates to oral pharmaceutical and cosmetic compositions having a cellulite therapeutic action comprising a complex of tritelpenes with free or phospholipids.
Description
본 발명은 셀룰라이트(cellulite)의 치료를 위한 식물 기원의 성분을 함유한 약제 및 화장품 조성물에 관한 것이다.The present invention relates to pharmaceutical and cosmetic compositions containing ingredients of plant origin for the treatment of cellulite.
보다 상세하게, 본 발명은 포도(Vitis vinifera extracts) 추출물, 은행(Ginkgo biloba) 후라보노이드류 이량체, 그리고 센텔라 아시아티카(Centella asiatica) 트리텔펜류와 같은 활성 성분을 함유한 셀룰라이트(cellulite) 치료를 위한 약제 및 화장품 경구 조성물에 관한 것이다.
More specifically, the present invention is grape ( Vitis vinifera extracts extract, Ginkgo biloba ) flavonoids dimer, and pharmaceutical and cosmetic oral compositions for the treatment of cellulite containing active ingredients such as Centella asiatica tritelpenes.
셀룰라이트(cellulite)는 서구 인구의, 특히 여성에 있어서, 비만에 걸리지 않은 보통 신체 체중의 많은 성인 여성을 포함하여 주목할만한 증가 퍼센트에 영향이 있다. 셀룰라이트는 지방층병변(panniculopathy) 상태와 연관이 있고, 부족한 말초 순환(peripheral circulation), 부종(oedema), 섬유증(fibrosis)과 변화된 지방세포 물질대사의 특징이 있으며, 이상적인 치료는 모든 이들 양상을 고려해야 한다.
Cellulite affects a noticeable increase in the western population, especially in women, including many adult women of normal body weight who are not obese. Cellulite is associated with a panniculopathy condition, characterized by poor peripheral circulation, oedema, fibrosis and altered fat cell metabolism, and ideal treatment should consider all these aspects. do.
셀룰라이트 치료용 경구용 조성물을 제공하기 위함이다.
It is to provide an oral composition for treating cellulite.
[발명의 상세한 설명]Detailed description of the invention
본 발명에 따르면, 활성 성분은 유리형(free form) 또는 인지질(phospholipids)과 착체를 이루고 있다.According to the invention, the active ingredient is complexed with free form or phospholipids.
셀룰라이트(cellulite)는 서구 인구의, 특히 여성에 있어서, 비만에 걸리지 않은 보통 신체 체중의 많은 성인 여성을 포함하여 주목할만한 증가 퍼센트에 영향이 있다. 셀룰라이트는 지방층병변(panniculopathy) 상태와 연관이 있고, 부족한 말초 순환(peripheral circulation), 부종(oedema), 섬유증(fibrosis)과 변화된 지방세포 물질대사의 특징이 있으며, 이상적인 치료는 모든 이들 양상을 고려해야 한다.Cellulite affects a noticeable increase in the western population, especially in women, including many adult women of normal body weight who are not obese. Cellulite is associated with a panniculopathy condition, characterized by poor peripheral circulation, oedema, fibrosis and altered fat cell metabolism, and ideal treatment should consider all these aspects. do.
셀룰라이트의 치료를 위한 많은 약제 및 화장품 조성물은 시장에서 즉시 입수가능하다 : 식물 기원의 예를 들어, 담쟁이덩쿨(ivy), 마로니에(horse-chestmut) 또는 콜라 트리(kola tree)(Centella asiatica) 추출물, 카페인(caffeine), 베타아드레날린성 흥분제(beta-adrenergic stimulants), 메틸잔틴(methylxanthines) 그리고 이와 같은 활성 성분들에 일반적으로 기초화된 것이다. 그러나, 진실로 효과가 입증된 것은 없고, 종종 식이요법에 기인한 개선이 있을지라도 그들 자신의 조성물 용도보다는 조성물의 용도와 관련된 것이었다.Many pharmaceutical and cosmetic compositions for the treatment of cellulite are readily available on the market: for example of plant origin, extracts of ivy, horse-chestmut or kola tree (Centella asiatica) Caffeine, beta-adrenergic stimulants, methylxanthines, and the like based on these active ingredients. However, nothing really has been proven effective, and often associated with the use of the composition rather than their own use, even with improvements due to diet.
식물기원의 활성 성분의 합제를 함유한 경구용 약제 및/또는 화장품 조성물은, 본 발명의 목적하는, 셀룰라이트의 치료, 피하지방의 축적과 "오렌지 껍질" 피부의 뚜렷한 감소에 최선의 결과를 주는 것이고, 고맙게도 다양한 성분의 다른 활성의 합제를 이루며, 항부종(antioedema), 항포스포디에스테라시스(antiphosphodiesterasis), 바소키네틱(vasokinetic) 활성을 발휘하고 콜라겐 생성을 촉진한다. 발명의 조성물은 하지 정맥부전증(venous insufficiency of the lower limbs)의 치료에 효과적이라는 것 역시 증명되었다.Oral pharmaceutical and / or cosmetic compositions containing a combination of plant-derived active ingredients give the best results for the treatment of cellulite, the accumulation of subcutaneous fat and a marked reduction in the "orange peel" skin of the present invention. Thankfully, it combines different activities of various components, exerts antioedema, antiphosphodiesterasis, vasokinetic activity and promotes collagen production. The compositions of the invention have also been demonstrated to be effective in the treatment of venous insufficiency of the lower limbs.
본 발명의 조성물의 모든 활성 성분은 알려져 있고, 약제 및/또는 화장품에 사용된다 ; 그러나 조성물은 상승 효과를 보여주고, 각각 사용된 단일 활동의 활성은 합제로 사용된 활성의 것보다 훨씬 낮다는 것에 주목해야 한다.All active ingredients of the compositions of the invention are known and used in medicaments and / or cosmetics; However, it should be noted that the compositions show a synergistic effect and that the activity of each single activity used is much lower than that of the combination used.
본 발명의 조성물은 포도(Vitis vinifera) 추출물을 용량단위(unit dose) 당 10 내지 500 mg, 은행(Ginkgo biloba) 후라보노이드류 이량체 10 내지 500 mg 및 센텔라 아시아티카(Centella asiatica) 10 내지 500 mg 또는 대응하는 인지질착체의 균등량을 포함할 수 있다.
The composition of the present invention is grape ( Vitis vinifera extract from 10 to 500 mg per unit dose, Ginkgo biloba ) flavonoid dimer 10 to 500 mg and Centella asiatica asiatica ) 10 to 500 mg or an equivalent amount of the corresponding phospholipid complex.
성분 a) - c) 의 유리형태는 상업적으로 유용하다.The free form of components a) -c) is commercially available.
포도(Vitis vinifera) 추출물의 인지질 착체(이하 "성분 a"라 한다)는 유럽특허 제275,224호에 기재되어 있다. 이 추출물은 포도(Vitis vinifera) 종자 중에 포함된 폴리페놀 분획으로 구성되며, 갈릭산(gallic acid), 카테친(catechin) 및 에피카테친(epicatechin) 단량체, 이량체, 삼량체, 사량체, 오량체, 육량체 및 칠량체를 유리형태 또는 갈릭산과의 에스텔 형태로 포함한다. Vitis Phospholipid complexes of vinifera ) extracts (hereinafter referred to as "component a") are described in EP 275,224. The extract is grapes ( Vitis vinifera ), consisting of polyphenol fractions contained in seeds, containing gallic acid, catechin and epicatechin monomers, dimers, trimers, tetramers, pentamers, hexamers and hepters In free form or in ester form with gallic acid.
시험관내 또는 생체실험에서 추출물의 높은 항산화제능력을 보였으며(실험모델에 의존적으로, 비타민 E의 항산화능 보다 10 내지 200 배 이상 높았다), 대부분의 반응선 기종(radical species)을 제거할 수 있었고, 유해효능에 반작용을 보였다. 더욱이 추출물은 잔틴-옥시다제(xanthine-oxidase)와 킬레이트 Cu++ 및Fe+++를 억제할 수 있으며, 따라서, 조직 중 유리라디칼의 효소 촉매적 생산을 예방할 수 있었다. 마지막으로, 포도(Vinis vinifera) 추출물은 콜라게나제(collagenase) 및 다른 푸로테아제(proteases)를 억제하며, 그로 인해 UV 자극에 따른 단백질 분해효소의 유해작용으로부터, 그리고 피부의 염증반응 과정 중에서 연조직 및 피부를 보호하고 ; 더욱이 추출물은 피부 및, 미세혈관 및 모세혈관과 같은 순환구조물에 대하여 선택적 친화력을 갖으며, 따라서, 순환기계에 대한 보호작용 역시 한다.In vitro or in vivo experiments showed a high antioxidant capacity of the extract (depending on the experimental model, 10 to 200 times higher than the antioxidant capacity of vitamin E), was able to remove most of the radical species It has a negative effect on the harmful effects. Moreover, the extract could inhibit xanthine-oxidase and chelate Cu ++ and Fe +++ , thus preventing the enzymatic catalytic production of free radicals in tissues. Finally, grapes ( Vinis vinifera ) extracts inhibit collagenase and other proteases, thereby protecting soft tissues and skin from the harmful effects of proteolytic enzymes upon UV stimulation and during the inflammatory process of the skin; Moreover, the extract has a selective affinity for skin and circulatory structures such as microvessels and capillaries, thus also protecting the circulatory system.
은행(Ginkgo biloba) 후라보노이드류 이량체와 인지질과의 착체(이하, "성분 b"라 한다)은, 유럽 특허 제0275005호에 기재되어 있으며, 은행(Ginko biloba) 후라본류 이량체의 유리형태와 동일한 효력을 갖지만, 활성물질의 더 큰 지속방출을 유도하며, 생물학적 활성(bioavailablity)이 더 우수하다. 은행(Ginkgo biloba) 후라보노이드류 이량체는 특히 비만세포(mast cells)로부터 히스타민과 cAMP 포스포디에스테라제의 방출을 억제한다는 점에서 혈관작용제로서 효능이 있다. 특히, cAMP 포스포디에스테라제의 억제는 cAMP 수치를 증가시키고 ; cAMP는 지방세포(lipocytes)대사를 활성화시키기 때문에 이들 착체화합물은 지질분해작용을 하고 미세혈관관류(microvascular perfusion) 및 피부영양(cutaneous trophism)을 개선시킨다.Bank ( Ginkgo biloba ) complexes of flavonoid dimers and phospholipids (hereinafter referred to as "component b") are described in European Patent No. 0275005, Ginko biloba ) has the same potency as the free form of flavonoid dimers, but induces greater sustained release of the active substance and better bioavailablity. Bank ( Ginkgo biloba ) Flavonoid dimers are particularly effective as vascular agents in that they inhibit the release of histamine and cAMP phosphodiesterase from mast cells. In particular, inhibition of cAMP phosphodiesterase increases cAMP levels; Because cAMP activates lipocyte metabolism, these complexes act to lipolyse and improve microvascular perfusion and cutaneous trophism.
센텔라 아시아티카(Centella asiatica) 추출물의 인지질 착체(이하 "성분 c"라 한다)는 유럽 특허 제0283713호에 기재되어 있다. 이 추출물은 콜라겐 대사에 높은 활성을 보이는 3개의 상이한 분자물의 4 : 3 : 3 혼합물로 구성되며 ; 아시아티코사이드(asiaticoside), 아시아틱산(asiatic acid) 및 마데카식산(madecassic acid)으로 구성되어 있다. 이들 분자물들은 아미노산, 주로 엘-푸로린(L-proline)과 엘-하이드록시푸로린(L-hydroxyproline)의 섬유아세포(fibroblasts)의 소비를 개선시켰으며, 이들 아미노산은 양과 질 모든 면에서 콜라겐 구조 중 가장 중요한 아미노산이다. 개선된 콜라겐 생합성은 퇴화된 노화섬유를 새섬유로 빠른 대체를 일으키게 한다. Centella asiatica phospholipid complexes (hereinafter referred to as "component c") of asiatica ) extracts are described in European Patent No. 0283713. This extract consists of a 4: 3: 3 mixture of three different molecular molecules that show high activity in collagen metabolism; It is composed of asiaticoside, asiatic acid and madecassic acid. These molecules have improved the consumption of fibroblasts of amino acids, mainly L-proline and L-hydroxyproline, and these amino acids have collagen structures in both quantity and quality. Among the most important amino acids. Improved collagen biosynthesis causes rapid replacement of degraded aging fibers with new fibers.
본 발명에 따른 조성물은, 적당한 제형으로 경구적으로 투여되며, 액상제제(시럽, 용액, 현탁제 등) 또는 고형제제(정제, 슈가코팅된 환제, 캅셀제, 저작정 등)등이 있다. 이들 제제는 "레밍톤 파마슈티칼 핸드북"(Remington's Pharmaceutical Handbook), Mack Publishing Co., NY, USA 에 기재된 관용의 방법으로 적당한 부형제를 사용하여 제조될 수 있다.
The composition according to the present invention is administered orally in a suitable formulation, and may include liquid preparations (syrups, solutions, suspensions, etc.) or solid preparations (tablets, sugar-coated pills, capsules, chewable tablets, etc.). These formulations can be prepared using suitable excipients by the conventional methods described in "Remington's Pharmaceutical Handbook", Mack Publishing Co., NY, USA.
본 발명에 따르면 셀룰라이트 치료용 식물기원의 경구용 약제 및 화장품 조성물을 얻을 수 있다는 특장점이 있다.According to the present invention has the advantage that it can obtain oral pharmaceutical and cosmetic compositions of plant origin for cellulite treatment.
본 발명에 따른 조성물의 실시예를 하기에 기재하였다.
Examples of compositions according to the invention are described below.
[실시예][Example]
실시예 1 : 정제 Example 1 : Tablet
포도(Vitis vinifera) 추출물의 인지질 착체 240 mg Vitis vinifera ) 240 mg phospholipid complex
은행(Ginko biloba) 후라보노이드류 이량체의 인지질 착체 100 mgBank ( Ginko biloba ) Phospholipid complex of flavonoid dimer 100 mg
센텔라 아시아티카(Centella asiatica) 트리텔펜류의 Centella asiatica asiatica ) tritelene
인지질 착체 60 mgPhospholipid Complex 60 mg
소디움 클로스카라멜로스 28 mgSodium Clos Caramelose 28 mg
실리콘 디옥사이노 8 mgSilicon Dioxino 8 mg
탈크 4 mg
Talc 4 mg
실시예Example 2 2 : :
포도(Vitis vinifera) 추출물 150 mg Vitis vinifera extract 150 mg
은행(Ginko biloba) 후라보노이드류 이량체 100 mgBank ( Ginko biloba ) flavonoid dimer 100 mg
센텔라 아시아티카(Centella asiatica) 트리텔펜류 10 mg Centella asiatica asiatica ) Tritelenes 10 mg
디칼슘포스페이트 이수화물 150 mgDicalcium phosphate dihydrate 150 mg
미결정 셀룰로스 100 mg100 mg of microcrystalline cellulose
클로스 카라멜로스 소디움 28 mgClos Caramelose Sodium 28 mg
실리콘 디옥사이드 8 mgSilicon dioxide 8 mg
마그네슘 스테아레이트 9 mgMagnesium Stearate 9 mg
탈크 3 mgTalc 3 mg
Claims (4)
b) 은행(Ginkgo biloba) 후라보노이드류 이량체 또는 그의 인지질과의 착체 ;
c) 센텔라 아시아티카(Centella asiatica) 또는 그의 인지질과의 착체,
와 관용의 부형제 및 담체를 혼합물 중에 포함한 셀룰라이트(cellulite) 치료용 경구용 약제 조성물.a) Vitis vinifera ) extract or its complex with phospholipids;
b) Ginkgo biloba) flavonoid complexes of acids and dimer or a phospholipid;
c) Centella Asiatica asiatica ) or its complex with phospholipids,
Oral pharmaceutical composition for treating cellulite, comprising a conventional excipient and a carrier in a mixture.
b) 은행(Ginkgo biloba) 후라보노이드류 이량체 또는 그의 인지질과의 착체 ;
c) 센텔라 아시아티카(Centella asiatica) 또는 그의 인지질과의 착체를,
포함하는 하지(lower limbs) 정맥부전증(venous insufficiency) 치료용 경구용 약제 조성물.a) Vitis vinifera ) extract or its complex with phospholipids;
b) Ginkgo biloba) flavonoid complexes of acids and dimer or a phospholipid;
c) Centella Asiatica asiatica ) or its complex with phospholipids,
Oral pharmaceutical composition for the treatment of lower limbs venous insufficiency.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2003A001789 | 2003-09-19 | ||
| IT001789A ITMI20031789A1 (en) | 2003-09-19 | 2003-09-19 | PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR TREATMENT |
| PCT/EP2004/010148 WO2005027947A1 (en) | 2003-09-19 | 2004-09-10 | Oral compositions for the treatment of cellulite |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067004760A Division KR101186096B1 (en) | 2003-09-19 | 2004-09-10 | Oral compositions for the treatment of cellulite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20110047280A true KR20110047280A (en) | 2011-05-06 |
Family
ID=34362407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067004760A KR101186096B1 (en) | 2003-09-19 | 2004-09-10 | Oral compositions for the treatment of cellulite |
| KR1020117009257A KR20110047280A (en) | 2003-09-19 | 2004-09-10 | Oral Compositions for the Treatment of Cellulite |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067004760A KR101186096B1 (en) | 2003-09-19 | 2004-09-10 | Oral compositions for the treatment of cellulite |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7691422B2 (en) |
| EP (1) | EP1663267B1 (en) |
| JP (1) | JP5537764B2 (en) |
| KR (2) | KR101186096B1 (en) |
| CN (1) | CN100566734C (en) |
| AT (1) | ATE357925T1 (en) |
| AU (1) | AU2004273598B2 (en) |
| CA (1) | CA2539229C (en) |
| CY (1) | CY1106561T1 (en) |
| DE (1) | DE602004005603T2 (en) |
| DK (1) | DK1663267T3 (en) |
| ES (1) | ES2285528T3 (en) |
| HK (1) | HK1093901A1 (en) |
| IL (1) | IL174353A0 (en) |
| IT (1) | ITMI20031789A1 (en) |
| NO (1) | NO334499B1 (en) |
| NZ (1) | NZ545972A (en) |
| PL (1) | PL1663267T3 (en) |
| PT (1) | PT1663267E (en) |
| RU (1) | RU2355389C2 (en) |
| SI (1) | SI1663267T1 (en) |
| WO (1) | WO2005027947A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT104241B (en) | 2008-10-29 | 2012-03-06 | Stargate Produtos Farmaceuticos Dieteticos E Nutricionais Lda | COMPOSITIONS INCORPORATING CELLULITE REDUCING AGENTS AND ASSOCIATED INESTETISMS AND FORMULATIONS CONTAINING THEM |
| CN104906153A (en) * | 2015-06-09 | 2015-09-16 | 邳州鑫源生物制品有限公司 | Technological method for efficiently extracting ginkgo flavone |
| CN104940253A (en) * | 2015-06-29 | 2015-09-30 | 兰捷 | Method for extracting high-purity total flavonoids from ginkgo leaves |
| KR20200115927A (en) * | 2019-03-29 | 2020-10-08 | 주식회사 유니베라 | Composition containing grape leaf extract and centella asiatica extract for improvement of venous circulation disorder |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1201151B (en) * | 1987-01-14 | 1989-01-27 | Indena Spa | PHOSPHOLIPID COMPLEXES WITH EXTRACTS FROM VITIS VINIFERA, PROCEDURE FOR THEIR PREPARATION AND COMPOSITIONS THAT CONTAIN THEM |
| IT1201149B (en) * | 1987-01-14 | 1989-01-27 | Indena Spa | BIOFLAVONOID COMPLEXES WITH PHOSPHOLIPIDS, THEIR PREPARATION, USE AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS |
| IT1203515B (en) | 1987-02-26 | 1989-02-15 | Indena Spa | SAPONINE COMPLEXES WITH PHOSPHOLIPIDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM |
| EP1276457B1 (en) * | 2000-04-18 | 2011-12-14 | Medestea Internazionale S.p.A. | A composition based on natural extracts useful in the prevention and treatment of cutaneous wrinkles |
| AU2002258649A1 (en) | 2001-03-30 | 2002-10-28 | Rhodia Inc. | Aqeuous suspension of nanoparticles comprising an agrochemical active ingredient |
| ITMI20011022A1 (en) | 2001-05-17 | 2002-11-17 | Indena Spa | PHARMACEUTICAL AND COSMETIC COMPOSITIONS AGAINST SKIN AGING |
| ITMI20031427A1 (en) | 2003-07-11 | 2005-01-12 | Indena Spa | COMBINATIONS OF VASOACTIVE AGENTS, THEIR USE IN THE PHARMACEUTICAL AND COSMETIC FIELD AND THE FORMULATIONS THAT CONTAIN THEM |
-
2003
- 2003-09-19 IT IT001789A patent/ITMI20031789A1/en unknown
-
2004
- 2004-09-10 CN CNB2004800267572A patent/CN100566734C/en not_active Expired - Fee Related
- 2004-09-10 PT PT04786933T patent/PT1663267E/en unknown
- 2004-09-10 EP EP04786933A patent/EP1663267B1/en not_active Not-in-force
- 2004-09-10 ES ES04786933T patent/ES2285528T3/en active Active
- 2004-09-10 RU RU2006108386/15A patent/RU2355389C2/en not_active IP Right Cessation
- 2004-09-10 DK DK04786933T patent/DK1663267T3/en active
- 2004-09-10 JP JP2006526567A patent/JP5537764B2/en not_active Expired - Fee Related
- 2004-09-10 SI SI200430256T patent/SI1663267T1/en unknown
- 2004-09-10 PL PL04786933T patent/PL1663267T3/en unknown
- 2004-09-10 CA CA2539229A patent/CA2539229C/en not_active Expired - Fee Related
- 2004-09-10 KR KR1020067004760A patent/KR101186096B1/en active IP Right Grant
- 2004-09-10 WO PCT/EP2004/010148 patent/WO2005027947A1/en active IP Right Grant
- 2004-09-10 KR KR1020117009257A patent/KR20110047280A/en not_active Application Discontinuation
- 2004-09-10 AT AT04786933T patent/ATE357925T1/en active
- 2004-09-10 AU AU2004273598A patent/AU2004273598B2/en not_active Ceased
- 2004-09-10 DE DE602004005603T patent/DE602004005603T2/en active Active
- 2004-09-10 US US10/570,943 patent/US7691422B2/en not_active Expired - Fee Related
- 2004-09-10 NZ NZ545972A patent/NZ545972A/en unknown
-
2006
- 2006-03-16 NO NO20061223A patent/NO334499B1/en not_active IP Right Cessation
- 2006-03-16 IL IL174353A patent/IL174353A0/en active IP Right Grant
-
2007
- 2007-01-10 HK HK07100325.9A patent/HK1093901A1/en not_active IP Right Cessation
- 2007-05-07 CY CY20071100593T patent/CY1106561T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN100566734C (en) | 2009-12-09 |
| DE602004005603T2 (en) | 2008-01-24 |
| AU2004273598A1 (en) | 2005-03-31 |
| DK1663267T3 (en) | 2007-07-30 |
| EP1663267B1 (en) | 2007-03-28 |
| KR20060101456A (en) | 2006-09-25 |
| EP1663267A1 (en) | 2006-06-07 |
| RU2355389C2 (en) | 2009-05-20 |
| US7691422B2 (en) | 2010-04-06 |
| NO20061223L (en) | 2006-04-19 |
| CA2539229C (en) | 2015-07-21 |
| AU2004273598B2 (en) | 2009-10-08 |
| ITMI20031789A1 (en) | 2005-03-20 |
| US20060292249A1 (en) | 2006-12-28 |
| NO334499B1 (en) | 2014-03-17 |
| ES2285528T3 (en) | 2007-11-16 |
| RU2006108386A (en) | 2006-09-10 |
| ATE357925T1 (en) | 2007-04-15 |
| CN1852726A (en) | 2006-10-25 |
| IL174353A0 (en) | 2006-08-01 |
| DE602004005603D1 (en) | 2007-05-10 |
| KR101186096B1 (en) | 2012-09-25 |
| NZ545972A (en) | 2009-04-30 |
| PL1663267T3 (en) | 2007-08-31 |
| WO2005027947A1 (en) | 2005-03-31 |
| HK1093901A1 (en) | 2007-03-16 |
| CY1106561T1 (en) | 2012-01-25 |
| CA2539229A1 (en) | 2005-03-31 |
| PT1663267E (en) | 2007-06-25 |
| JP5537764B2 (en) | 2014-07-02 |
| SI1663267T1 (en) | 2007-06-30 |
| JP2007505850A (en) | 2007-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU761947B2 (en) | Skin and tissue care and/or treatment agent | |
| US8343557B2 (en) | Compositions incorporating agents for reducing cellulite and unaesthetic appearance associated therewith and formulations containing them | |
| US6756065B1 (en) | Anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems | |
| US20070184134A1 (en) | Pharmaceutical and cosmetic composition against skin aging | |
| EP1392335B1 (en) | Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite | |
| JP2006524236A (en) | Slimming composition | |
| CN105168106B (en) | One kind three spends whitening and softening skin facial mask liquid and preparation method thereof | |
| CA2386770C (en) | Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba | |
| AU2002342279A1 (en) | Pharmaceutical and cosmetic compositions against skin aging | |
| KR101186096B1 (en) | Oral compositions for the treatment of cellulite | |
| RU2485965C2 (en) | Compartment-specific dual combination of herbal extracts of ginkgo biloba and ginseng | |
| KR20080001820A (en) | A composition for skin external application containing antioxidant components for improving skin wrinkle and skin whitening | |
| KR100308491B1 (en) | Composition for growthing hair | |
| Kvalheim et al. | SKIN CARE PRODUCTS AND THEIR EFFECT ON AGING SKIN | |
| ITCL20080016A1 (en) | PREPARATION FOR FLEBOTONIC ACTION, FLEBOTROPA, ANTIEDEMIGENA AND ANTIOXIDANT OF THE VASAL WALL BASED ON DIOSMINE, CENTELLA ASIATICA (E.S. TITLE 20% OF ASIATICOSIDE) VITIS VINIFERA (E.S. TIT. 95% OF PROANTOCIANIDINE), RUSCUS ACULEATUS (E.S. TITLE 5% |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| J201 | Request for trial against refusal decision | ||
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20120327 Effective date: 20131015 |